|
gptkbp:instance_of
|
gptkb:Antihero
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
B01 AF01
|
|
gptkbp:brand
|
gptkb:Xarelto
|
|
gptkbp:casnumber
|
366789-02-8
|
|
gptkbp:category
|
gptkb:C
not recommended
|
|
gptkbp:chemical_formula
|
C19 H18 Cl N3 O5 S
|
|
gptkbp:class
|
factor Xa inhibitor
|
|
gptkbp:clinical_trial
|
gptkb:ROCKET_AF
RECORD1
RECORD2
|
|
gptkbp:contraindication
|
active bleeding
severe renal impairment
hypersensitivity to rivaroxaban
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xarelto
|
|
gptkbp:ingredients
|
gptkb:rivaroxaban
|
|
gptkbp:interacts_with
|
NSAIDs
antiplatelet agents
other anticoagulants
|
|
gptkbp:invention
|
2024
|
|
gptkbp:legal_status
|
prescription only
|
|
gptkbp:lifespan
|
5 to 9 hours
|
|
gptkbp:manufacturer
|
gptkb:Johnson_&_Johnson
gptkb:Bayer_AG
|
|
gptkbp:marketed_as
|
gptkb:2011
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
nausea
bleeding
liver enzyme abnormalities
|
|
gptkbp:strength
|
10 mg
15 mg
20 mg
|
|
gptkbp:used_for
|
preventing blood clots
reducing the risk of stroke
treating deep vein thrombosis
treating pulmonary embolism
|
|
gptkbp:bfsParent
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:bfsLayer
|
4
|